Immune-based combination therapy for esophageal cancer

被引：21

作者：

Wang, Huiling ^{[1
,2
]}

Xu, Yufei ^{[1
,2
]}

Zuo, Fengli ^{[1
,2
]}

Liu, Junzhi ^{[3
]}

Yang, Jiqiao ^{[1
,2
,4
]}

机构：

[1] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Integrat Med,State Key Lab Biotherapy, Chengdu, Peoples R China

[2] Collaborat Innovat Ctr, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp, Breast Ctr, Chengdu, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

esophageal cancer; immunotherapy; chemotherapy; radiotherapy; combination therapy; SQUAMOUS-CELL CARCINOMA; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; ADJUVANT NIVOLUMAB; 1ST-LINE TREATMENT; SINGLE-ARM; CHEMOTHERAPY; IMMUNOTHERAPY; PEMBROLIZUMAB; MULTICENTER;

D O I：

10.3389/fimmu.2022.1020290

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Esophageal cancer (EC) is an aggressive malignancy raising a healthcare concern worldwide. Standard treatment options include surgical resection, chemotherapy, radiation therapy, and targeted molecular therapy. The five-year survival rate for all stages of EC is approximately 20%, ranging from 5% to 47%, with a high recurrence rate and poor prognosis after treatment. Immunotherapy has shown better efficacy and tolerance than conventional therapies for several malignancies. Immunotherapy of EC, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy, has shown clinical advantages. In particular, monoclonal antibodies against PD-1 have a satisfactory role in combination therapy and are recommended for first- or second-line treatments. Here, we present a systematic summary and analysis of immunotherapy-based combination therapies for EC.

引用

页数：15

共 117 条

[1] Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 [J].

Adenis, Antoine ;

Kulkarni, Amit S. ;

Girotto, Gustavo C. ;

de la Fouchardiere, Christelle ;

Senellart, Helene ;

van Laarhoven, Hanneke W. M. ;

Mansoor, Wasat ;

Al-Rajabi, Raed ;

Norquist, Josephine ;

Amonkar, Mayur ;

Suryawanshi, Shailaja ;

Bhagia, Pooja ;

Metges, Jean-Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04) :382-+

[2] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[3] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[4] Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy [J].

Bai, Yuzhuo ;

Wang, Yun ;

Zhang, Xudong ;

Fu, Jianhua ;

Xing, Xiuli ;

Wang, Chunlan ;

Gao, Longlan ;

Liu, Yu ;

Shi, Li .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 570

[5] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[6] First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [J].

Bang, Y. J. ;

Giaccone, G. ;

Im, S. A. ;

Oh, D. Y. ;

Bauer, T. M. ;

Nordstrom, J. L. ;

Li, H. ;

Chichili, G. R. ;

Moore, P. A. ;

Hong, S. ;

Stewart, S. J. ;

Baughman, J. E. ;

Lechleider, R. J. ;

Burris, H. A. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :855-861

[7] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study [J].

Bang, Yung-Jue ;

Kang, Yoon-Koo ;

Catenacci, Daniel V. ;

Muro, Kei ;

Fuchs, Charles S. ;

Geva, Ravit ;

Hara, Hiroki ;

Golan, Talia ;

Garrido, Marcelo ;

Jalal, Shadia I. ;

Borg, Christophe ;

Doi, Toshihiko ;

Yoon, Harry H. ;

Savage, Mary J. ;

Wang, Jiangdian ;

Dalal, Rita P. ;

Shah, Sukrut ;

Wainberg, Zev A. ;

Chung, Hyun Cheol .

GASTRIC CANCER, 2019, 22 (04) :828-837

[8] Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers [J].

Baxter, Mark A. ;

Middleton, Fearghas ;

Cagney, Hannah P. ;

Petty, Russell D. .

BRITISH JOURNAL OF CANCER, 2021, 125 (08) :1068-1079

[9] T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies [J].

Biernacki, Melinda A. ;

Brault, Michelle ;

Bleakley, Marie .

CANCER JOURNAL, 2019, 25 (03) :179-190

[10] Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study [J].

Boku, N. ;

Ryu, M. H. ;

Oh, D-Y. ;

Oh, S. C. ;

Chung, H. C. ;

Lee, K-W. ;

Omori, T. ;

Shitara, K. ;

Sakuramoto, S. ;

Chung, I. J. ;

Yamaguchi, K. ;

Kato, K. ;

Sym, S. J. ;

Kadowaki, S. ;

Tsuji, K. ;

Chen, J-S. ;

Bai, L-Y. ;

Chen, L-T. ;

Kang, Y-K. .

ANNALS OF ONCOLOGY, 2020, 31 :S1192-S1192

← 1 2 3 4 5 6 7 8 9 10 →